Susquehanna Fundamental Investments LLC acquired a new stake in shares of Twist Bioscience Corporation (NASDAQ:TWST – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 34,189 shares of the company’s stock, valued at approximately $3,517,000. Susquehanna Fundamental Investments LLC owned approximately 0.05% of Twist Bioscience as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Two Sigma Securities LLC bought a new position in Twist Bioscience in the second quarter valued at about $322,000. Empowered Funds LLC bought a new stake in shares of Twist Bioscience during the second quarter worth about $214,000. Corient Private Wealth LP bought a new stake in shares of Twist Bioscience during the second quarter worth about $2,226,000. Bank of America Corp DE acquired a new position in shares of Twist Bioscience in the second quarter valued at approximately $94,922,000. Finally, Odyssean LLC acquired a new position in shares of Twist Bioscience in the second quarter valued at approximately $2,699,000.
Analyst Upgrades and Downgrades
A number of research analysts recently issued reports on TWST shares. Piper Sandler raised their price objective on shares of Twist Bioscience from $85.00 to $115.00 and gave the company an “overweight” rating in a report on Wednesday, August 5th. UBS Group set a $89.00 price target on shares of Twist Bioscience in a research report on Monday, June 15th. Leerink Partners set a $110.00 price target on shares of Twist Bioscience in a research note on Thursday, July 16th. Barclays lifted their price target on shares of Twist Bioscience from $65.00 to $95.00 and gave the stock an “overweight” rating in a report on Wednesday, June 24th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research note on Wednesday, June 24th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $98.30.
Twist Bioscience Stock Down 1.7%
Twist Bioscience stock opened at $139.00 on Tuesday. The firm has a market cap of $8.72 billion, a price-to-earnings ratio of -62.61 and a beta of 2.14. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $155.44. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67. The firm has a 50 day moving average price of $108.03 and a two-hundred day moving average price of $74.64.
Twist Bioscience (NASDAQ:TWST – Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). The business had revenue of $118.38 million for the quarter, compared to analyst estimates of $114.55 million. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The business’s revenue was up 23.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.33 earnings per share. Equities analysts predict that Twist Bioscience Corporation will post -2.12 EPS for the current year.
Insider Activity at Twist Bioscience
In other news, CEO Emily M. Leproust sold 113,318 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $125.16, for a total transaction of $14,182,880.88. Following the completion of the sale, the chief executive officer directly owned 818,938 shares of the company’s stock, valued at $102,498,280.08. The trade was a 12.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Dennis Cho sold 14,205 shares of the firm’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $89.75, for a total value of $1,274,898.75. Following the completion of the transaction, the insider owned 105,141 shares in the company, valued at $9,436,404.75. This represents a 11.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 193,099 shares of company stock worth $24,026,581 over the last quarter. 3.08% of the stock is currently owned by insiders.
About Twist Bioscience
Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.
At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.
Featured Stories
- Five stocks we like better than Twist Bioscience
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
